CONJUGATION OF SMALL RIBOSOMAL INHIBITORS TO ANTIBODIES

Information

  • Research Project
  • 3491432
  • ApplicationId
    3491432
  • Core Project Number
    R43CA042613
  • Full Project Number
    1R43CA042613-01A1
  • Serial Number
    42613
  • FOA Number
  • Sub Project Id
  • Project Start Date
    9/30/1987 - 37 years ago
  • Project End Date
    3/29/1988 - 36 years ago
  • Program Officer Name
  • Budget Start Date
    9/30/1987 - 37 years ago
  • Budget End Date
    3/29/1988 - 36 years ago
  • Fiscal Year
    1987
  • Support Year
    1
  • Suffix
    A1
  • Award Notice Date
    9/28/1987 - 37 years ago
Organizations

CONJUGATION OF SMALL RIBOSOMAL INHIBITORS TO ANTIBODIES

We propose a new series of small molecular weight, natural products that are similar to higher plant toxins in their mechanisms of action, inhibiting protein synthesis at the level of the ribosome. All inhibit in vivo translation in cell free systems. Some are cytotoxic to eucaryotic cells at low concentrations (ID50 100 pg/ml) and thus behave like the "intact" dimeric toxins ricin and abrin; others are not cytotoxic at relatively high concentrations (10 ug/ml) and are similar to the ribosomal inactivating protein (RIPs) such as gelonin. Monoclonal antibodies (MA) are proposed as vehicles to facilitate binding and internalization of the non-cytotoxic (RIP-like) molecules and to enhance selectivity of the cytotoxic (intact toxin-like) molecules. We will conjugate two of the RIP-like molecules that differ only in one site of acetylation and one toxin-like molecule to an anti- melanoma MA and test for inhibition of protein synthesis and overall cytotoxicity and selectivity with antigen-positive and antigen-negative melanoma cells. Their conjugates may have equivalent potency but not suffer the poor delivery due to nonspecific uptake as occurs for higher molecular weight toxins. They are also not likely to suffer from drug-induced cross- resistance, as occurs with drugs currently used in chemotherapy. Should either or both of these approaches prove feasible, it will be possible to construct several generations of a wide range of related anti-tumor agents that have unique mechanisms of action that will be important new agents for the treatment of cancer.

IC Name
NATIONAL CANCER INSTITUTE
  • Activity
    R43
  • Administering IC
    CA
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    395
  • Ed Inst. Type
  • Funding ICs
  • Funding Mechanism
  • Study Section
    SSS
  • Study Section Name
  • Organization Name
    NEORX CORPORATION
  • Organization Department
  • Organization DUNS
  • Organization City
    SEATTLE
  • Organization State
    WA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    98119
  • Organization District
    UNITED STATES